Shire faces battle against ADHD generics

Shire, the maker of ADHD drugs Adderall XR and Vyvanse, had an excellent Q1 but now faces a challenge: Its two top products are threatened by a generic that Teva brought to market on April 2, BNet Pharma reports. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.